Glenmark Pharmaceuticals Ltd
GLENMARK price chart
Daily close · 5-year history
Instrument details
Identifiers & classification
- Symbol
- GLENMARK
- MB Code
- MBEQU267
- ISIN
- INE935A01035
- BSE code
- 532296
- Industry group
- Pharmaceuticals & Biotechnology
- Screener
- View peers →
Latest earnings
Most recent declared quarter
- Quarter
- Mar 2026
- Revenue
- 3770.59 Cr
- Net profit
- 301.32 Cr
- EPS
- 10.68
- YoY revenue
- +15.80%
Company documents
12 PDFs across 4 categories
Audited annual reports & financial statements
Earnings call transcripts & Q&A
Investor decks & strategy updates
Exchange filings & corporate announcements
Corporate timeline
Earnings, news & corporate actions for GLENMARK
Glenmark Pharmaceuticals said March 2026 quarter net profit jumped 6381.94% to Rs 301.41 crore from Rs 4.65 crore a year earlier, while s…
Glenmark Pharma Q4 net profit jumped to ₹301.4 crore and FY26 PAT rose to ₹1,362 crore; board also recommended a 250% dividend and approv…
Glenmark Pharmaceuticals reported a strong Q3 for the period ending December 31, 2025, with net profit rising 15.9% to ₹403 crore and rev…
Glenmark Pharma's Monroe facility has received USFDA clearance with an Establishment Inspection Report (EIR) indicating Voluntary Action …
Glenmark Pharmaceuticals reported a 72.2% increase in Q2 profit to Rs 610.43 crore, attributed to a licensing deal with AbbVie for ISB 20…
Glenmark Pharmaceuticals Ltd. reported a significant profit increase of 72% and a revenue rise of 76.1%, reaching Rs 6,047 crore in Q2. T…
Glenmark Life Sciences IPO opened on July 27 at Rs 695-720. It was subscribed 44.17 times by July 29, showing strong investor interest. T…
Dividend of ₹2.50 per share
Ex-date corporate action
Price returns
Historical performance
Technicals
Indicator consensus